| 產品名稱 |
9D10 |
| 商品貨號 |
B163855 |
| Organism |
Homo sapiens, human |
| Tissue |
spleen |
| Cell Type |
B lymphocyte; Epstein-Barr virus (EBV) transforme |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 Cells Contain HERPESVIRUS
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody is specific for the lipopolysaccharide of the Fisher immunotype 4 of P. aeruginosa. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa lipopolysaccharide (LPS) of Fisher immunotype 4 (IATS type 1) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa lipopolysaccharide (LPS) of Fisher immunotype 4 (IATS type 1) |
| Comments |
B cells from peripheral blood of an individual known to have been exposed to P. aeruginosa were transformed with Epstein-Barr virus (EBV). The antibody is specific for the lipopolysaccharide of the Fisher immunotype 4 of P. aeruginosa. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
|
| Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium.
Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) cells/ml. Do not allow the cell concentration to reach 2 X 10(6) cells/ml.
Interval: Maintain cell density between 2 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| STR Profile |
Amelogenin: X,Y CSF1PO: 10,12 D13S317: 9,13 D16S539: 11,13 D5S818: 11,12 D7S820: 8,11 THO1: 6,7 TPOX: 8 vWA: 14,17 |
| Isotype |
IgM |
| Population Doubling Time |
24 to 36 hrs |
| Name of Depositor |
Miles Inc., Genetics Systems Corporation |
| U.S. Patent Number |
|
| References |
Siadak AW, Lostrom ME. Human monoclonal antibodies to serotypic lipopolysaccharide determinants on Gram-negative bacteria and their production. US Patent 4,834,975 dated May 30 1989
|
